Abstract
Purpose: Growth retardation is a common complication of chronic kidney disease (CKD) in children. Treatment with recombinant human growth hormone (rhGH) has been used to help short children with CKD to attain a height more in keeping with their age group, but the scientific evidence regarding the effect of rhGH on final height is scarce. Methods: Final heights of children with CKD receiving rhGH treatment (cases) were compared with final heights of a matched cohort of children with CKD that did not receive rhGH therapy (controls). Results: Sixty-eight rhGH-treated cases (44 boys) were compared with 92 untreated controls (60 boys). Mean duration of rhGH therapy was 4.2 ± 0.9 years; rhGH dose was 0.3 ± 0.07 mg/kg/week. Height SDS at baseline was lower in rhGH-treated patients than in controls (−2.00 ± 1.02 versus −0.96 ± 1.11, p < 0.001). Baseline height SDS was significantly lower than target height SDS in both groups. Height SDS significantly improved from baseline to final height attainment in rhGH-treated patients, while it slightly decreased in controls (mean SDS variation 0.69 ± 1.05 in rhGH-treated cases versus −0.15 ± 1.2 in controls). Final height SDS was −1.25 ± 1.06 in rhGH-treated cases and −1.06 ± 1.17 in controls (p = 0.29). Target adjusted final height SDS was −0.91 ± 1.03 in rhGH-treated cases and −0.61 ± 1.17 in controls (p = 0.1). Conclusions: Long-term rhGH therapy is able to reduce the linear growth deceleration of children with CKD, and ultimately to improve their final height, reducing the difference with target height.
| Original language | English |
|---|---|
| Pages (from-to) | 325-331 |
| Number of pages | 7 |
| Journal | Journal of Endocrinological Investigation |
| Volume | 41 |
| Issue number | 3 |
| DOIs | |
| Publication status | E-pub ahead of print - Aug 17 2017 |
Fingerprint
Keywords
- Child
- Chronic kidney disease
- Growth hormone
- Height
- Nutritional status
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Endocrinology
Cite this
Growth hormone treatment improves final height and nutritional status of children with chronic kidney disease and growth deceleration. / Bizzarri, C.; Lonero, A.; Delvecchio, M.; Cavallo, L.; Faienza, M. F.; Giordano, M.; Dello Strologo, L.; Cappa, M.
In: Journal of Endocrinological Investigation, Vol. 41, No. 3, 17.08.2017, p. 325-331.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Growth hormone treatment improves final height and nutritional status of children with chronic kidney disease and growth deceleration
AU - Bizzarri, C.
AU - Lonero, A.
AU - Delvecchio, M.
AU - Cavallo, L.
AU - Faienza, M. F.
AU - Giordano, M.
AU - Dello Strologo, L.
AU - Cappa, M.
PY - 2017/8/17
Y1 - 2017/8/17
N2 - Purpose: Growth retardation is a common complication of chronic kidney disease (CKD) in children. Treatment with recombinant human growth hormone (rhGH) has been used to help short children with CKD to attain a height more in keeping with their age group, but the scientific evidence regarding the effect of rhGH on final height is scarce. Methods: Final heights of children with CKD receiving rhGH treatment (cases) were compared with final heights of a matched cohort of children with CKD that did not receive rhGH therapy (controls). Results: Sixty-eight rhGH-treated cases (44 boys) were compared with 92 untreated controls (60 boys). Mean duration of rhGH therapy was 4.2 ± 0.9 years; rhGH dose was 0.3 ± 0.07 mg/kg/week. Height SDS at baseline was lower in rhGH-treated patients than in controls (−2.00 ± 1.02 versus −0.96 ± 1.11, p < 0.001). Baseline height SDS was significantly lower than target height SDS in both groups. Height SDS significantly improved from baseline to final height attainment in rhGH-treated patients, while it slightly decreased in controls (mean SDS variation 0.69 ± 1.05 in rhGH-treated cases versus −0.15 ± 1.2 in controls). Final height SDS was −1.25 ± 1.06 in rhGH-treated cases and −1.06 ± 1.17 in controls (p = 0.29). Target adjusted final height SDS was −0.91 ± 1.03 in rhGH-treated cases and −0.61 ± 1.17 in controls (p = 0.1). Conclusions: Long-term rhGH therapy is able to reduce the linear growth deceleration of children with CKD, and ultimately to improve their final height, reducing the difference with target height.
AB - Purpose: Growth retardation is a common complication of chronic kidney disease (CKD) in children. Treatment with recombinant human growth hormone (rhGH) has been used to help short children with CKD to attain a height more in keeping with their age group, but the scientific evidence regarding the effect of rhGH on final height is scarce. Methods: Final heights of children with CKD receiving rhGH treatment (cases) were compared with final heights of a matched cohort of children with CKD that did not receive rhGH therapy (controls). Results: Sixty-eight rhGH-treated cases (44 boys) were compared with 92 untreated controls (60 boys). Mean duration of rhGH therapy was 4.2 ± 0.9 years; rhGH dose was 0.3 ± 0.07 mg/kg/week. Height SDS at baseline was lower in rhGH-treated patients than in controls (−2.00 ± 1.02 versus −0.96 ± 1.11, p < 0.001). Baseline height SDS was significantly lower than target height SDS in both groups. Height SDS significantly improved from baseline to final height attainment in rhGH-treated patients, while it slightly decreased in controls (mean SDS variation 0.69 ± 1.05 in rhGH-treated cases versus −0.15 ± 1.2 in controls). Final height SDS was −1.25 ± 1.06 in rhGH-treated cases and −1.06 ± 1.17 in controls (p = 0.29). Target adjusted final height SDS was −0.91 ± 1.03 in rhGH-treated cases and −0.61 ± 1.17 in controls (p = 0.1). Conclusions: Long-term rhGH therapy is able to reduce the linear growth deceleration of children with CKD, and ultimately to improve their final height, reducing the difference with target height.
KW - Child
KW - Chronic kidney disease
KW - Growth hormone
KW - Height
KW - Nutritional status
UR - http://www.scopus.com/inward/record.url?scp=85027853306&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85027853306&partnerID=8YFLogxK
U2 - 10.1007/s40618-017-0745-4
DO - 10.1007/s40618-017-0745-4
M3 - Article
AN - SCOPUS:85027853306
VL - 41
SP - 325
EP - 331
JO - Journal of Endocrinological Investigation
JF - Journal of Endocrinological Investigation
SN - 0391-4097
IS - 3
ER -